Drug Trial Radar · NCT04403100
Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: "The Hope Coalition - 1"
Last checked: Nov 20, 2026Latest source record: Jan 26, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,968
Planned (sponsor's estimate)
Start
Jun 3, 2020
Primary completion
Feb 1, 2021
Study completion Feb 1, 2021
Sponsor
- Lead sponsor
- CardresearchAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Cardresearch - Cardiologia Assistencial e de Pesquisa LTDA; Cytel Inc.
- First posted
- May 27, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The COVID-19 pandemic has been characterized by high morbidity and mortality, especially in certain subgroups of patients. To date, no treatment has been shown to be effective in controlling this disease in hospitalized patients with moderate and / or severe cases of this disease. Hydroxychloroquine and lopinavir / ritonavir have been shown to inhibit SARS-CoV viral replication in experimental severe acute respiratory symptoms models and have similar activity against SARS-CoV2. Although widely used in studies of critically ill patients, to date, no study has demonstrated its role on the treatment of high-risk, newly diagnosed patients with COVID-19 and mild symptoms.
Conditions
- COVID-19
- Coronavirus Infection
- Virus Disease
- Acute Respiratory Infection
- SARS-CoV Infection
Interventions
Hydroxychloroquine Sulfate TabletsDrug
Tablets of 400 mg: Loading dose of 02 tablets followed by one tablet of 400 mg orally on the following 09 days
Lopinavir/ Ritonavir Oral TabletDrug
tablets of 200/ 50 mg; Loading dose of 04 tablets twice a day on day 1 followed by two tablets twice a day on the following 09 days
Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral TabletsDrug
Hydroxychloroquine Oral Tablet 400 mg: Loading dose of 02 tablets followed by one tablet of 400 mg orally on the following 09 days plus Lopinavir/ Ritonavir Oral Tablet of 200/ 50 mg: Loading dose of 04 tablets twice a day on day 1 followed by two tablets twice a day on the following 09 days
PlaceboDrug
Placebo tablets - 01 tablet twice daily from day 01 through day 10.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants who were hospitalized for progression of COVID-19 diseaseTime frame: Measuring during 28-day period since randomization (Intention to treat analysis)
- Proportion of participants who died due to COVID-19 progression and/ or complicationsTime frame: Measuring during 28-day period since randomization (Intention to treat analysis)
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
CARDRESEARCH - Cardiologia Assistencial e de Pesquisa
Belo Horizonte, Minas Gerais, Brazil · Recruiting
Pontificia Universidade Catolica de Minas Gerais
Belo Horizonte, Minas Gerais, Brazil · Not yet recruiting
Fundo Municipal de Saúde de Betim
Betim, Minas Gerais, Brazil · Recruiting
Universidade Federal de Ouro Preto
Ouro Preto, Minas Gerais, Brazil · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.